fda compounding semaglutide crackdown news november 2025 How Crackdowns Are Affecting GLP-1 Use In November 2025 Drug Safety: Recalls

Semaglutide, marketed as Wegovy, functions solely as a GLP-1 receptor agonist and typically produces weight loss ranging from 10% to 15% of body weight

Another possible application is ingestible beauty/nutricosmetics that are nutrient-dense with collagen innovations targeted at GLP-1 users

(PDF) Duda, J.M.*, Moser, A.D.* Ironside, M., Null, K.E., Holsen, L.M., Zuo, C.S., Du, F., Esfand, S.M., Chen, X., Perlo, S., Richards, C.E., Lobien, R., Alexander, M., Misra, M., Goldstein, J.M.#, Pizzagalli, D.A.# (2024)

Overall sales grew modestly (~1% nominal, ~2% ex-FX) versus 2024

Daxko Launches GLP-1 Program for Fitness Operators The software giants new Elevate Wellness program helps gyms and clubs link members with licensed telehealth providers to offer GLP-1s and other services Daxko is helping fitness operators join the growing gym-as-a-clinic movement